Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 6 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
Campaign fuels efforts to find better treatments for blood cancers in children
NBC Dallas Fort Worth· 2 hours agoLeukemia and Lymphoma Society's (LLS) Dare to Dream project hopes to raise money for research of...
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
Pharmaceutical Technology via Yahoo Finance· 2 days agoBased on the latest STARGLO trial results, there is potential to extend Columvi into earlier lines...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 2 days agoFate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients...
Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment
Investor's Business Daily· 1 day agoNurix's approach degrades a protein called BTK. Doing so blocks defective B cells, which can drive...
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks via Yahoo Finance· 7 hours agoUpdated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 5 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
Roche’s Columvi offers extended survival in Phase III DLBCL trial
Clinical Trials Arena via Yahoo Finance· 2 days agoRoche has reported findings from the Phase III STARGLO clinical trial where Columvi, in combination...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 1 day agoMB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center to treat...
Biotest wins FDA approval for plasma protein therapy
Pharmaceutical Technology via Yahoo Finance· 1 day agoAntibody deficiency syndrome is caused by an immunoglobulin level significantly under the standard range or a failure of immunoglobulin function. The...
